{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:13:48Z","timestamp":1768994028168,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To investigate this issue, we conducted a retrospective follow-up (393 \u00b1 87 days) of 1,746 consecutive patients, hospitalized with and surviving COVID-19 pneumonia at a single tertiary medical center between April and December 2020. Survivors received either 30-day post-discharge antithrombotic treatment regime using prophylactic direct oral anticoagulation (DOAC; <jats:italic>n<\/jats:italic> = 1,002) or dipyridamole (<jats:italic>n<\/jats:italic> = 304), or, no post-discharge antithrombotic treatment (Ctrl; <jats:italic>n<\/jats:italic> = 440). All-cause mortality, as well as cardiovascular mortality (CVM) and further cardiovascular outcomes (CVO) resulting in hospitalization due to pulmonary embolism (PE), myocardial infarction (MI) and stroke were investigated during the follow-up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>While no major bleeding events occured during follow-up in the treatment groups, Ctrl showed a high but evenly distributed rate all-cause mortality. All-cause mortality (CVM) was attenuated by prophylactic DOAC (0.6%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and dipyridamole (0.7%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). This effect was also evident for both therapies after propensity score analyses using weighted binary logistic regression [DOAC: <jats:italic>B<\/jats:italic> = \u22123.33 (0.60), <jats:italic>P<\/jats:italic> &amp;lt; 0.001 and dipyridamole: <jats:italic>B<\/jats:italic> = \u22123.04 (0.76), <jats:italic>P<\/jats:italic> &amp;lt; 0.001]. While both treatment groups displayed a reduced rate of CVM [DOAC: <jats:italic>B<\/jats:italic> = \u22122.69 (0.74), <jats:italic>P<\/jats:italic> &amp;lt; 0.001 and dipyridamole: <jats:italic>B<\/jats:italic> = \u221217.95 (0.37), <jats:italic>P<\/jats:italic> &amp;lt; 0.001], the effect in the DOAC group was driven by reduction of both PE [<jats:italic>B<\/jats:italic>\u22123.12 (1.42), <jats:italic>P<\/jats:italic> = 0.012] and stroke [<jats:italic>B<\/jats:italic> = \u22123.08 (1.23), <jats:italic>P<\/jats:italic> = 0.028]. Dipyridamole significantly reduced rates of PE alone [<jats:italic>B<\/jats:italic> = \u221217.05 (1.01), <jats:italic>P<\/jats:italic> &amp;lt; 0.001].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Late cardiovascular events and all-cause mortality were high in the year following hospitalization for COVID-19. Application of prophylactic DOAC or dipyridamole in the early post-discharge period improved mid- and long-term CVO and all-cause mortality in COVID-19 survivors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.916156","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:08:56Z","timestamp":1659071336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors"],"prefix":"10.3389","volume":"9","author":[{"given":"Lukas J.","family":"Motloch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jirak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Mirna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paruir A.","family":"Davtyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina A.","family":"Lakman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana F.","family":"Gareeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton V.","family":"Tyurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruslan M.","family":"Gumerov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon T.","family":"Matskeplishvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin N.","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benzhi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Topf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta C.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudin","family":"Pistulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naufal S.","family":"Zagidullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5271\/sjweh.3960","article-title":"Return-to-work, disabilities and occupational health in the age of COVID-19: Scand","volume":"47","author":"Godeau","year":"2021","journal-title":"J Work Environ Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijcard.2020.09.064","article-title":"Antithrombotic therapy in patients with COVID-19?","volume":"324","author":"Godino","year":"2021","journal-title":"Int J Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"015","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau","year":"2015","journal-title":"BMC Cardiovasc Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1074248420958973","article-title":"COVID-19 infection: viral macro- and micro-vascular coagulopathy and thromboembolism\/prophylactic and therapeutic management","volume":"26","author":"Manolis","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.thromres.2020.12.001","article-title":"Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study","volume":"198","author":"Rashidi","year":"2021","journal-title":"Thromb Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood.2020010529","article-title":"Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry","volume":"137","author":"Giannis","year":"2021","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the inspiration randomized clinical trial","volume":"325","author":"Sadeghipour","year":"2021","journal-title":"JAMA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with COVID-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMe2111151","article-title":"Surviving COVID-19 with Heparin?","volume":"385","author":"Ten Cate","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","first-page":"1","article-title":"Chronic oral anticoagulation and clinical outcome in Hospitalized COVID-19 patients [Published Online Ahead of print, 2021 May 14]","volume-title":"Cardiovasc Drugs Ther.","author":"Russo","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ehf2.13136","article-title":"Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study","volume":"8","author":"Jirak","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11239-020-02212-6","article-title":"Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?","volume":"51","author":"Paar","year":"2021","journal-title":"J Thromb Thrombolysis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/CIRCULATIONAHA.120.053311","article-title":"Multiple biomarker approach to risk stratification in COVID-19","volume":"143","author":"Smilowitz","year":"2021","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"021","DOI":"10.1038\/s41598-021-85646-z","article-title":"The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome","volume":"11","author":"Mengozzi","year":"2021","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajh.26102","article-title":"Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis","volume":"96","author":"Meizlish","year":"2021","journal-title":"Am J Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.blre.2020.100745","article-title":"Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system","volume":"46","author":"Lazzaroni","year":"2021","journal-title":"Blood Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm Sin B."},{"key":"B22","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"7","author":"Xie","year":"2022","journal-title":"Nat Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/jth.14929","article-title":"Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Spyropoulos","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B25","unstructured":"Version 8 of the temporal recommendations for the prevention, diagnosis and treatment of the novel coronavirus infection COVID-19 by Russian Ministry of Healthcare"},{"key":"B26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet."},{"key":"B27","year":""},{"key":"B28","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). endorsed by: association for European paediatric and congenital cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1182\/blood.2020008086","article-title":"Postdischarge venous thromboembolism following hospital admission with COVID-19","volume":"136","author":"Roberts","year":"2020","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/rth2.12485","article-title":"Vascular thromboembolic events following COVID-19 hospital discharge: incidence and risk factors","volume":"5","author":"Eswaran","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.120.049465","article-title":"Unexpected features of cardiac pathology in COVID-19 infection","volume":"142","author":"Fox","year":"2020","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3201\/eid2608.201097","article-title":"Prolonged persistence of SARS-CoV-2 RNA in body fluids","volume":"26","author":"Sun","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/cid\/ciab611","article-title":"Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): A prospective cohort study","volume":"74","author":"See\u00dfle","year":"2022","journal-title":"Clin Infect Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.phrs.2014.05.008","article-title":"Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel?","volume":"87","author":"Balakumar","year":"2014","journal-title":"Pharmacol Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/thoraxjnl-2020-215818","article-title":"\u2018Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19","volume":"76","author":"Mandal","year":"2021","journal-title":"Thorax"},{"key":"B38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/STROKEAHA.118.023954","article-title":"Antiplatelet therapy in ischemic stroke and transient ischemic attack","volume":"50","author":"Hackam","year":"2019","journal-title":"Stroke."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2174\/138161212799504731","article-title":"Inflammation-induced thrombosis: mechanisms, disease associations and management","volume":"18","author":"Aksu","year":"2012","journal-title":"Curr Pharm Des."},{"key":"B41","unstructured":"WHO Tracking SARS-CoV-2 variants2021"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.916156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:09:04Z","timestamp":1659071344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.916156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":41,"alternative-id":["10.3389\/fcvm.2022.916156"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.916156","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"article-number":"916156"}}